ClinicalTrials.gg
CompletedNCT03292185Updated Nov 18, 2019

A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects

A Phase 1 interventional study of insulin degludec/liraglutide and insulin degludec in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-11-18.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2018, 8 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.

Enrollment
66th of 70
24 · median 384
Started
2017
with 4 others
Phase 1
8 of 70
1 open now
Registered
56th of 70
by date
Lead sponsor
56 of 70
Novo Nordisk A/S

Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 66th largest by enrollment, is one of 5 that started in 2017, is one of 8 in phase 1, and was the 56th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About insulin degludec

insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The main purpose of the trial is to compare the bioavailability (extent of drug absorption into the circulation) of insulin degludec and liraglutide as part of a combination product insulin degludec/liraglutide compared to the corresponding doses of single, separate injections of insulin degludec and liraglutide. Participants will receive all three test substances. The order of trial administration will be allocated by chance. During the trial period, serials of blood samples will be collected from the participants at three dosing periods, in order to determine the concentration of insulin degludec and liraglutide. The total volume of blood taken throughout the whole trial period will be less than 400 mL. Participants will be asked to stay on daytime and overnight in the trial sites on some predefined days. For other outpatient days, participants need to attend the trial site as required for drug administration or required assessments.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 24 is below the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female Chinese subjects, who are considered to be generally healthy, based on assessment of medical history, physical examination, and clinical laboratory data, as judged by the investigator
  • Age between 18 to 45 years (both inclusive) at the time of signing
  • (BMI) between 19.0 and 24.0 kg/sqm (both inclusive)
  • Body weight at least 50.0 kg
  • Fasting plasma glucose less than 6.1 mmol/L (110 mg/dL)

Exclusion criteria

Exclusion criteria:

  • Female who is pregnant, breast-feeding or intends to become pregnant or is of not using an adequate methods throughout the trial including follow-up period. Adequate contraceptive measures are sterilisation, intrauterine device (IUD), oral contraceptives or barrier methods
  • Donation of any blood or plasma in the past month or in excess of 400 mL within the 90 days preceding screening or surgery or trauma with more than 400 mL blood loss within the 90 days preceding screening
  • History or presence of cancer, or any cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal, endocrine (incl. diabetes and recurrent hypoglycaemia), haematological, dermatological, venereal, neurological, psychiatric diseases or other major disorders that might have impact on the trial result, as judged by the investigator
  • Use of any prescription or non-prescription medication, except for paracetamol, acetylsalicylic acid, contraceptives and vitamins (mega-dose vitamin therapy not allowed, dose judged by the investigator) within 2 weeks prior to screening
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    IDeglira-IDeg-Liraglutide

    Treatment sequence first Insulin Degludec/Liraglutide, then Insulin Degludec, then Liraglutide

    Drug: insulin degludec/liraglutide · Drug: insulin degludec · Drug: liraglutide

  • Experimental
    IDeglira-Liraglutide-IDeg

    Treatment sequence first Insulin Degludec/Liraglutide, then Liraglutide, then Insulin Degludec

    Drug: insulin degludec/liraglutide · Drug: insulin degludec · Drug: liraglutide

  • Experimental
    IDeg-Liraglutide-IDeglira

    Treatment sequence first Isulin Degludec, then Liraglutide, then Insulin Degludec/Liraglutide

    Drug: insulin degludec/liraglutide · Drug: insulin degludec · Drug: liraglutide

  • Experimental
    IDeg-IDeglira-Liraglutide

    Treatment sequence first Insulin Degludec, then Insulin Degludec/Liraglutide, then Liraglutide

    Drug: insulin degludec/liraglutide · Drug: insulin degludec · Drug: liraglutide

  • Experimental
    Liraglutide-IDeg-IDeglira

    Treatment sequence first Liraglutide, then Insulin Degludec, then Insulin Degludec/Liraglutide

    Drug: insulin degludec/liraglutide · Drug: insulin degludec · Drug: liraglutide

  • Experimental
    Liraglutide-IDeglira-IDeg

    Treatment sequence first Liraglutide, then Insulin Degludec/Liraglutide, then Insulin Degludec

    Drug: insulin degludec/liraglutide · Drug: insulin degludec · Drug: liraglutide

Interventions

  • Druginsulin degludec/liraglutide

    Drug pages: Insulin degludec · Liraglutide

    Insulin Degludec/Liraglutide combination product with 0.61 mg Liraglutide and 17 U Insulin Degludec, single dose administration under the skin in the thigh.

  • 17 U Insulin Degludec, single dose administration under the skin in the thigh.

  • 0.6 mg Liraglutide, single dose administration under the skin in the thigh

07

What researchers measure

Primary outcomes

  1. Area under the serum insulin degludec concentration time curve

    Calculated based on insulin degludec concentration in serum

    Time frame: From 0 to last quantifiable observation after single dose of insulin degludec/liraglutide and insulin degludec, assessments from 0 hours to 120 hours

  2. Area under the plasma liraglutide concentration time curve

    Calculated based on liraglutide concentration in plasma

    Time frame: from 0 to last quantifiable observation after single dose of insulin degludec/liraglutide and liraglutide, assessments from 0 hours to 72 hours

Secondary outcomes

  1. Area under the serum insulin degludec concentration time curve from 0 to infinity after single dose

    Calculated based on insulin degludec measured in serum

    Time frame: 0 hours to 120 hours

  2. Maximum observed serum insulin degludec concentration

    Calculated based on insulin degludec measured in serum

    Time frame: 0 hours to 120 hours

  3. Time to maximum serum insulin degludec concentration

    Calculated based on insulin degludec measured in serum

    Time frame: 0 hours to 120 hours

  4. Terminal elimination half-life for insulin degludec

    Calculated based on insulin degludec measured in serum

    Time frame: 0 hours to 120 hours

  5. Area under the plasma liraglutide concentration time curve from 0 to infinity after single dose

    Calculated based on liraglutide measured in plasma

    Time frame: 0 hours to 72 hours

  6. Maximum observed plasma liraglutide concentration

    Calculated based on liraglutide measured in plasma

    Time frame: 0 hours to 72 hours

  7. Time to maximum plasma liraglutide concentration

    Calculated based on liraglutide measured in plasma

    Time frame: 0 hours to 72 hours

  8. Terminal elimination half-life of liraglutide

    Calculated based on liraglutide measured in plasma

    Time frame: 0 hours to 72 hours

  9. Number of treatment emergent adverse events

    Count

    Time frame: Visit 2 (Day 1, randomisation), Visit 5 (7-14 days after last dosing visit)

  10. Number of treatment emergent hypoglycaemic episodes

    Count

    Time frame: Visit 2 (Day 1, randomisation), Visit 5 (7-14 days after last dosing visit)

  11. Local tolerability at the injection site

    Count

    Time frame: Visit 2 (Day 1, randomisation), Visit 5 (7-14 days after last dosing visit)

08

Study locations

1 site
  • Novo Nordisk Investigational Site
    Beijing, Beijing 100032, China
09

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Jan 2018, 3 months.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 3 months is below that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2017
First posted
Sep 25, 2017
StartActual
Sep 29, 2017
Primary completionActual
Jan 2, 2018
CompletionActual
Jan 2, 2018
Last update
Nov 18, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03292185
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Sep 25, 2017
Start date
Sep 29, 2017
Primary completion
Jan 2, 2018
Completion
Jan 2, 2018
Last update
Nov 18, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin degludec · Liraglutide

Start the discussion